Who is sponsoring NCT04212377?

NCT04212377 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04212377?

Interventions in NCT04212377: Dendritic Cells for endometrial cancer.

What condition does NCT04212377 study?

NCT04212377 studies Endometrial Cancer.

Is NCT04212377 still recruiting?

NCT04212377 is currently completed. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT04212377: DECENDO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients

Completed Phase 2 Last updated 11 January 2024

What this trial tests

Phase 2 trial testing Dendritic Cells for endometrial cancer in Endometrial Cancer in 8 participants. Completed in 9 March 2021.

Timeline

8 April 2019

Primary endpoint
9 March 2021

9 March 2021

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	8 April 2019
Primary completion	9 March 2021
Estimated completion	9 March 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Dendritic Cells for endometrial cancer — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Radboud University Medical Center

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prevention of infectious diseases through immunization is one of the greatest achievements of modern medicine. Nonetheless, considerable challenges remain for improving the efficacy of existing vaccines for therapeutic immunizations for diseases such as cancer. The investigators were amongst the first groups worldwide that introduced tumor antigen-loaded dendritic cell (DC)-based vaccines in the clinic1-3. Effective immune responses and favorable clinical outcomes have indeed been observed4-7. Thus far, mainly conventional in vitro generated monocyte-derived DCs (moDC) have been used in clinical trials worldwide. In the past 14 years the investigators have treated more than 375 patients and proven that DC therapy is feasible and non-toxic. The investigators observed that long lasting tumor specific T cell-mediated immunological responses are clearly linked to increased progression free survival as well as overall survival8. In conclusion, based on all these observations the investigators are convinced that pDC and myDC employ different, and probably more optimal mechanisms to combat cancer. In addition, based on in vitro data and preclinical studies that suggest that blood pDC and myDC act synergistically, the investigators hypothesize that the combination of myDC and pDC may induce stronger anti-tumor immune responses as compared to pDC or myDC alone, or moDC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.
Alard E, Butnariu AB, Grillo M, Kirkham C, et al · · 2020 · cited 62× · PMID 32645977 · DOI 10.3390/cancers12071826
Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.
Monti M, Ferrari G, Gazzurelli L, Bugatti M, et al · · 2024 · cited 22× · PMID 39020402 · DOI 10.1186/s13046-024-03121-9
Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy.
Hernández SS, Jakobsen MR, Bak RO. · · 2022 · cited 21× · PMID 36232698 · DOI 10.3390/ijms231911397
Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.
Koeneman BJ, Schreibelt G, Gorris MAJ, Hins-de Bree S, et al · · 2024 · cited 14× · PMID 38444861 · DOI 10.3389/fimmu.2024.1368103
Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to Treat Human Immunodeficiency Virus Infection?
van der Sluis RM, Egedal JH, Jakobsen MR. · · 2020 · cited 14× · PMID 32528903 · DOI 10.3389/fcimb.2020.00249
The progress of peptide vaccine clinical trials in gynecologic oncology.
Tang M, Cai JH, Diao HY, Guo WM, et al · · 2022 · cited 13× · PMID 35687860 · DOI 10.1080/21645515.2022.2062982
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.
Yusoh NA, Ahmad H, Vallis KA, Gill MR. · · 2025 · cited 11× · PMID 40518502 · DOI 10.1007/s12032-025-02812-3

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04212377 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04212377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing